STOCK WATCH

■ A FIRM owned by Remote Monitored Systems (RMS) will begin producing anti-viral face masks in January.

Pharm2Farm’s masks are designed to kill coronavirus on impact.

RMS’s core focus is operating drones that check railway lines and big factories for damage, but it bought Pharm2Farm in August.

Despite providing investors with an up-to-date timetable for production, shares in AIMlisted RMS slumped 25.5pc, or 0.65p, to 1.9p.